enGene Therapeutics Inc ENGN
1.96
0.04
2.08%
as of 25 Sep
- Market cap
- $128.7M
- P/E
- 0.0×
Follow ENGN
Insider Buys
alert about insiders buying in the last 12 month
| Dec '17 | Oct '21 | Dec '21 | Oct '22 | Dec '22 | Oct '23 | Oct '24 | Oct '25 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 46.20 | 4.79 | 4.42 | 0.57 | 16.25 | 16.87 | 6.30 |
Net Debt/EBITDA |
— | — | 0.00 | (0.54) | 0.17 | 2.80 | 3.47 | 1.42 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 129.01% | 0.00% | 10.60% | 7.22% | 6.92% |
Debt/Equity |
— | — | 0.00 | (0.40) | 0.00 | 0.13 | 0.08 | 0.09 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.00 | 0.00 | 0.61 | (24.60) | 0.24 | 0.88 | 0.85 |
Capex/Depreciation |
— | 0.00 | 0.00 | (0.64) | — | (1.82) | (10.16) | 0.58 |
Interest Coverage |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | — | 0.00% | 73.58% | (0.08%) | (306.36%) | (31.96%) | (53.28%) | |
| — | 0.00% | (0.34%) | (37.36%) | 0.04% | (95.65%) | (27.70%) | (44.05%) | |
ROIC |
— | — | 0.00% | 0.00% | 0.00% | (15,511.90%) | (68.69%) | 0.00% |
Return on Tangible Assets |
— | 0.00% | (18.17%) | (162.45%) | (8.04%) | (129.67%) | (23.58%) | (68.24%) |
Average Days of Receivables |
— | — | — | 0.00 | — | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | — | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | — | 0.00% | — | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | 0.00 | 0.00 | (27.08) | (0.24) | (36.16) | (1.30) | (1.97) |
Cash per Share |
— | — | 0.07 | 31.30 | 0.10 | 117.74 | 6.31 | 3.79 |
Shareholders Equity per Share |
— | — | (0.14) | (116.93) | (1.30) | 104.60 | 7.22 | 3.28 |
Interest Debt per Share |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | — | (0.14) | (116.93) | (1.30) | 104.60 | 7.22 | 3.28 |
Free Cash Flow |
— | 0.00 | 0.00 | (17.74) | (0.76) | (25.06) | (49.21) | (100.72) |
Working Capital |
— | 0.49 | 1.24 | 17.48 | (0.38) | 80.18 | 232.70 | 169.41 |
Capital Expenditures |
— | 0.00 | 0.00 | (0.15) | — | (0.32) | (0.92) | (1.48) |
Net Current Asset Value |
— | 0.49 | (132.16) | (77.94) | (135.64) | 70.97 | 208.80 | 147.63 |
| Other line items | ||||||||
Quick Ratio |
— | 0.00 | 3.27 | 4.28 | 0.35 | 15.97 | 16.28 | 6.09 |
Depreciation/Fixed assets |
— | 0.00 | 0.00 | 0.62 | — | 0.30 | 0.08 | (1.03) |
Cash ROIC |
— | 0.00% | 0.00% | 71.17% | 19.90% | (15.51%) | (9.27%) | (26.99%) |
Accounts Receivable Turnover |
— | — | — | — | — | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | — | — | — | — | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
— | — | — | 0.00 | — | 0.00 | 0.00 | 0.00 |
Revenue per Share |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | 0.00 | 0.00 | (26.85) | (0.24) | (35.70) | (1.28) | (1.94) |
Capex per Share |
— | 0.00 | 0.00 | (0.23) | 0.00 | (0.46) | (0.02) | (0.03) |
Average Receivables |
— | — | — | — | — | 1.84 | 1.34 | 0.63 |
Average Payables |
— | — | — | — | — | 0.94 | 1.28 | 4.05 |
Average Assets |
— | 0.25 | 65.97 | 77.68 | 77.98 | 109.50 | 199.07 | 266.32 |
Average Common Equity |
— | — | — | (39.45) | (40.36) | 34.19 | 172.55 | 220.16 |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates